Form D · Other
Belenos Biosciences, Inc.
New York, NY · CIK 0002030450
Offering snapshot reported Jul 17, 2024 · SEC filing
- Reported sold
- $48M Offering amount: $55M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 8, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 17, 2024 | Initial | $48,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-519049
Source: Form D, filed Jul 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bo Chen | Director |
| Tania Dimitrova | Executive |
| Megan Dow | Executive |
| Carl Gordon | Director |
| St John Donnie Mc Grath | Director, Executive |
| David Wang | Director |
Issuer details
Industry: Other (See others in industry)
Address:
601 Lexington Avenue, 54 Th Floor
New York, NY, 10022
New York, NY, 10022